biotech
Vaccinoma Hopes To Raise $17M from IPO
Filed in archive Corporate and Industrial News , Drugs, Vaccines and Therapeutics by ruth on April 28, 2006
Vaccinoma Hopes To Raise $17M from IPO
In Australia, Vaccinoma will be offering 17 million shares a $1.00 each in an initial public offering (IPO) starting on May 4, 2006. The funds will be used to produce and prepare a melanoma cancer vaccine for Phase 3 clinical trials. Previous studies in the US show that the vaccine, which has been almost 15 years in the making, is safe and effective in extending the lifespan of late-stage cancer patients.

"This drug has been "de-risked", so to speak, because it has been under development for over ten years and had no safety issues in over 600 people.

So investors can get into a cycle of development that is near its end and that will appeal to them.

It means they can invest in a company that has a drug that could be very important to Australia, which is potentially not very far from getting approved."


In addition to the melanoma cancer vaccine, part of the funds will also be used to push the company's breast cancer vaccine into Phase 1 human trials.

Read the full report from The Age: Vaccinoma wants $17 million from IPO.

Related Entries:

Permalink: Vaccinoma Hopes To Raise $17M from IPO
Tags: IPO  stocks  biotech  raise  vaccinoma  hopes+raise  vaccinoma+hopes  stem+cells 
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/20913
img Addthis img Ask img Blinklist img del.icio.us img Digg img Fark img Facebook img Google img Lycos img Ma.gnolia Add this page to Mister Wong Mr Wong img Netscape img Netvousz img Newsvine img Reddit img StumbleUpon img Slashdot img Tailrank img Technorati img Wink img Yahoo

Vote for Vaccinoma Hopes To Raise $17M from IPO:

  • Currently 6.67/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 6.67 out of 3 vote(s) cast.
 
Subscribe
Share It
RSSrss
See all blog subscribe options
Google google
What is RSS?
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Newsletter

TwitterFollow us on Twitter!